RBC Capital on Johnson & Johnson (JNJ): 'Oncology Portfolio Built for Long-Term Growth'
Tweet Send to a Friend
RBC Capital analyst Shagun Singh reiterated an Outperform rating and $181.00 price target on Johnson & Johnson (NYSE: JNJ).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
